Anti-inflammatory therapies in atopic dermatitis

被引:35
作者
Heratizadeh, A. [1 ]
Werfel, T. [1 ]
机构
[1] Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Carl Neuberg Str. 1, Hannover, Germany
关键词
atopic dermatitis; interleukin; molecule; receptor; treatment; ANTI-CD20 RITUXIMAB TREATMENT; HISTAMINE H4 RECEPTOR; ANTI-IGE THERAPY; CD8(+) T-CELLS; PHOSPHODIESTERASE INHIBITOR; TH17; CELLS; IFN-GAMMA; ALLERGIC DISORDERS; PEDIATRIC-PATIENTS; SKIN INFLAMMATION;
D O I
10.1111/all.13065
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The pathogenesis of atopic dermatitis (AD) is multifactorial and complex. Consequently, clinical signs and symptoms vary strongly depending on individually relevant trigger factors and the stage of the disease. So far, treatment of AD was commonly limited to topical treatment or, in more severe cases, to systemic drugs mostly approved for other indications than AD. However, emerging data on new anti-inflammatory agents have been published in the recent years. As these new substances specifically focus on immune responses in AD, these are partially considered as possible breakthrough' in the treatment of AD. Therapeutic strategies of the future appear to be customized' for inflammation in AD as they target pro-inflammatory, highly relevant cytokines and cytokine receptors, such as IL-4R, IL-13, IL-31, and IL-17. Further innovative therapeutic approaches aim to block the function of relevant molecules such as thymic stromal lymphopoietin, chemoattractant-receptor homologous molecule expressed on Th2 lymphocytes (CRTh2), and phosphodiesterase (PDE)-4 inhibitors. Recently, anti-inflammatory effects in AD by antagonizing the histamine (H)-4 receptor have also been detected. Finally, specific immunotherapy is under further investigation as treatment option for AD patients with clinically relevant sensitization.
引用
收藏
页码:1666 / 1675
页数:10
相关论文
共 110 条
[61]   IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells [J].
Nograles, Kristine E. ;
Zaba, Lisa C. ;
Shemer, Avner ;
Fuentes-Duculan, Judilyn ;
Cardinale, Irma ;
Kikuchi, Toyoko ;
Ramon, Michal ;
Bergman, Reuven ;
Krueger, James G. ;
Guttman-Yassky, Emma .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (06) :1244-1252
[62]   Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis [J].
Novak, Natalija ;
Bieber, Thomas ;
Hoffmann, Matthias ;
Foelster-Holst, Regina ;
Homey, Bernhard ;
Werfel, Thomas ;
Sager, Angelika ;
Zuberbier, Torsten .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 130 (04) :925-+
[63]   Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study [J].
Ohba, Fuminori ;
Matsuki, Shunji ;
Imayama, Shuhei ;
Matsuguma, Kyoko ;
Hojo, Seiichiro ;
Nomoto, Maiko ;
Akama, Hideto .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2016, 27 (05) :467-472
[64]   Mast cells and basophils in cutaneous immune responses [J].
Otsuka, A. ;
Kabashima, K. .
ALLERGY, 2015, 70 (02) :131-140
[65]   Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults [J].
Paller, Amy S. ;
Tom, Wynnis L. ;
Lebwohl, Mark G. ;
Blumenthal, Robin L. ;
Boguniewicz, Mark ;
Call, Robert S. ;
Eichenfield, Lawrence F. ;
Forsha, Douglass W. ;
Rees, William C. ;
Simpson, Eric L. ;
Spellman, Mary C. ;
Gold, Linda F. Stein ;
Zaenglein, Andrea L. ;
Hughes, Matilda H. ;
Zane, Lee T. ;
Hebert, Adelaide A. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (03) :494-+
[66]   Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy [J].
Ponte, Pedro ;
Paiva Lopes, Maria Joao .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (02) :355-356
[67]  
Prollenium Medical Technologies Inc, 2016, MULT DOUBL BLIND RAN
[68]   IL-13-stimulated human keratinocytes preferentially attract CD4+CCR4+ T cells:: Possible role in atopic dermatitis [J].
Purwar, Rahul ;
Werfel, Thomas ;
Wittmann, Miriam .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (05) :1043-1051
[69]   Treatment of severe refractory adult atopic dermatitis with ustekinumab [J].
Puya, Rafael ;
Alvarez-Lopez, Maria ;
Velez, Antonio ;
Casas Asuncion, Enrique ;
Carlos Moreno, Jose .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2012, 51 (01) :115-116
[70]   IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis [J].
Raap, Ulrike ;
Weissmantel, Sigo ;
Gehring, Manuela ;
Eisenberg, Anna M. ;
Kapp, Alexander ;
Foelster-Holst, Regina .
PEDIATRIC ALLERGY AND IMMUNOLOGY, 2012, 23 (03) :285-288